3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Steve Latham of DonateStock, Arianne Dowdell of Houston Methodist, and Howard Berman of Coya Therapeutics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from fintech to health care DEI — recently making headlines in Houston innovation.

Steve Latham, co-founder and CEO of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech toolThe sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

For the third time in his career, serial entrepreneur Steve Latham recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon. For his latest venture, Donate Stock, a tech platform that simplifies stock donation for both the donor and the beneficiary, he's focused on weathering whatever storm is incoming.

"We've raised more money to extend our runway, and we're keeping a super tight lid on expenses because your cash is your oxygen," he says. "There are companies going out of business in our industry right now that had really promising businesses but just spent too much money before they could get to the revenue phase."

He shares the background story on DonateStock and his own career on last week's Houston Innovators Podcast episode. Read more and stream the episode.

Arianne Dowdell, vice president and chief diversity, equity and inclusion officer at Houston Methodist

Arianne Dowdell spoke with InnovationMap about Houston Methodist's DEI initiatives — and how they will help develop the hospital of the future. Photo courtesy of Houston Methodist

Innovation and equity are two things they have to go together — and Houston Methodist knows that. Which is why Arianne Dowdell serves as vice president and chief diversity, equity and inclusion officer at Houston Methodist. Under her leadership, the health care provider is putting the patients at the forefront of the hospital system's priorities through its DEI initiatives.

In an interview with InnovationMap, Dowdell shares more about these ongoing initiatives and her role, as well as the importance of DEI in innovative health care.

"It doesn't matter if you're down here in the medical center or out in Baytown," she says. "The innovation and what we're thinking about and the technologies and the way that we communicate with our patients, all that is part of innovation, which helps our DEI initiatives become more successful in everything that we're doing." Read more.

Howard Berman, CEO of Coya Therapeutics

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo courtesy of Coya

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release. Howard Berman, CEO of Coya Therapeutics, has lead the company since February of 2021. Read more.

The sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech tool

Houston innovators podcast episode 167

Donating stock can be a smart way to offload assets and optimize a donation — but Steve Latham thought it was so cumbersome a process that it didn't even feel worth it.

"It was such a hassle that I never did it again," says Latham on the Houston Innovators Podcast.

That opportunity for innovation stuck with Latham as he advanced his career in AdTech in New York before moving back to Houston a few years ago. A serial entrepreneur, Latham was an early co-founder of the Houston Technology Center.

His latest venture is DonateStock — a tech platform that simplifies stock donation for both the donor and the beneficiary. The early version of Latham's vision was to clear up the lack of communication the original process had — nonprofits receiving stock donations were never notified about who made each donation.

The next phase for the fintech company, as Latham explains on the show, is to scale this idea by way of channel distribution, rather than just directly working between donor and nonprofit. He says he wants DonateStock to be a featured as an "easy button" option wherever donations are accepted online.

"Now that we've proven and shown that our process works," he says, "let's scale that to make that button available to the 20 or so online donation platforms."

In order to accomplish this goal, Latham is preparing to fundraise early this year, but it's a challenging time for fintech amid economic uncertainty, he says. So far, the company has raise $2.25 million from within the company's network along with angel and family office investment.

This is the third time in Latham's career that he's seen this recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon.

Latham shares more about the difference his company is making within the nonprofit sector, as well as his passion for Houston and its local tech ecosystem — which he's seen grow up from afar — on the podcast episode. Stream the episode below, or wherever you listen to your podcasts.

Houston-based DonateStock is $50,000 richer after claiming a recent pitch competition win. Photo via donatestock.com

Houston fintech startup snags Capital Factory's $50,000 pitch investment prize

winner, winner

Capital Factory, one of the most active startup investors with a presence across Texas, recently hosted a virtual pitch competition — and one Houston startup took home the big prize.

As a part of the Houston Tech Rodeo, Capital Factory hosted its $50K Houston Investment Challenge with five finalists — DonateStock, Elastique, Elemental Coatings, M&S Biotics, and ScalaMed. The panel of judges included Andy Cloyd, vice president of Revolution; Aleece Hobson, venture partner at HX Venture Fund; and Juliana Garaizar launch director of Greentown Labs.

DonateStock, a tech-enabled tool that automates the stock donation process, took home the big win. Steve Latham, founder and chairman of DonateStock, presented the company's pitch and explained how the tool has the potential to unlock $100 billion for nonprofits.

"A lot of people aren't aware about the benefits of donating stock," Latham explains. "If you're sitting on stock that you've owned or several years that's appreciated quite a bit. If you sell it, you pay capital gains tax — anywhere from 15 to 30 percent. If you donate it, you avoid the tax and you get a big write off, you can deduct the full market value of the donated stock."

He goes on to explain how only 2 percent of people donate stock — and its due to the archaic process that it takes. DonateStock's platform optimizes the education of donors, the connection of nonprofits to new donors, and the simplification of the process. What used to take hours now takes just 10 minutes, Latham says.

Nonprofits get a free page, free customer support, and there is no fee to be on the platform, and DonateStock makes a 2 percent transaction fee. The company already has 40 nonprofits on the platform, and over 70 in the queue to sign up. The goal, Latham says, is to have 900 organizations online by the end of the year. He's already seen a lot of interest in light of the pandemic.

"This is the time to solve this problem," Latham says. "If you have friends at nonprofits or charities, you know what the pandemic did to giving programs. They've all been devastated and they have gotta find new ways to diversify and grow their revenue."

DonateStock anticipates a seed round later this year. It's the third startup Latham has worked on with his co-founder.

"We see a path to building a billion-dollar company over the next five years while impacting millions of lives around the world," he says.

Each of the other finalists' consolation prize is a connection and a foot in the door at Capital Factory, says CEO Joshua Baer.

"Every time we do one of these, we meet a bunch of companies that we end up working with — and many of whom we end up investing in," he says at the virtual event. "We're going to be following up with all of the companies from today. Anyone who was a finalist and up on the stage is someone we are excited about and interested in working more closely with."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

Energy systems such as nuclear and geothermal
Energy supply chains
Energy-transition fuel and technology
Traditional energy

“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME